Lumexa Imaging (LMRI) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Consolidated Revenues: $264.2 million, up 5.1% year-over-year.

System-wide Revenue Growth: 6% driven by advanced modalities.

Revenue per Scan: Increased by 2.2% in the outpatient segment.

Adjusted EBITDA: $56.4 million, slightly up from $56.3 million in Q2 2025; adjusted EBITDA margin at 21.4%.

Net Income: $2.7 million, compared to a net loss of $7.2 million in Q2 2025; GAAP EPS of $0.03 and adjusted EPS of $0.20.

Free Cash Flow: Record high of $23.1 million, significantly improved from a negative $2.5 million in Q2 2025.

Net Leverage: Reduced to 3.6x from 5.7x a year ago.

2Strategic Updates and Business Highlights

Advanced Modalities: Represented 37.4% of total volume, a record high, with significant growth in PET (23.2%).

New Centers: Opened 2 de novo centers; targeting 8-10 openings annually, with 4 new centers announced in May.

Joint Ventures: Formed a significant partnership with the Hospital for Special Surgery, expanding into the New York metro area.

Technologist Advancement Academy: Graduated 100 technologists, enhancing workforce capabilities.

Lumexa Imaging Connect: Launched an integrated operating platform to improve patient and provider interactions.

3Forward Guidance and Outlook

Adjusted EBITDA Guidance: Narrowed to $235 million to $241 million for the full year, maintaining a midpoint of $238 million.

Revenue Guidance: Unchanged at $1.045 billion to $1.097 billion.

Adjusted EPS Guidance: Reiterated at $0.71 to $0.77 per share.

Seasonality: Anticipated 45% of earnings in the first half and 55% in the second half of 2026, with continued growth expected from de novo centers.

4Bad News, Challenges, or Points of Concern

Increased Operating Expenses: G&A expenses rose to $24.4 million, partly due to public company costs and stock-based compensation.

Payor Mix Shifts: Some minor shifts in payer mix were noted, although not significant enough to indicate a long-term trend.

Labor Constraints: The tight labor market for radiologists and technologists remains a challenge, although the company is implementing strategies to mitigate this issue.

5Notable Q&A Insights

Seasonal Trends: Management confirmed expectations for a natural seasonal ramp in the second half of the year, driven by de novo openings and increased demand.

Joint Venture Pipeline: Strong interest from health systems to expand outpatient imaging capabilities, with a robust pipeline for future partnerships.

Data Breach Impact: Minimal impact from a vendor-related data breach was reported, with no significant costs expected.

Capacity Management: The company is leveraging technology to address labor shortages and improve operational efficiency, including virtual MRI capabilities and teleradiology services. Overall, Lumexa Imaging reported solid growth in Q2 2026, driven by advanced imaging modalities and strategic partnerships, while navigating challenges related to operating expenses and labor constraints. The company remains optimistic about its growth trajectory and market opportunities.